Platinum

Overview

Platinum is under investigation for the treatment of Metastatic Breast Cancer, Non-small Cell Lung Cancer, Gastric Large Cell Neuroendocrine Carcinoma, Colorectal Large Cell Neuroendocrine Carcinoma, and Pancreatic Large Cell Neuroendocrine Carcinoma, among others. Platinum has been investigated for the treatment and supportive care of Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Primary Cancer, Non Small Cell Lung Cancer, and Primary Peritoneal Carcinoma, among others.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC	2025/05/16	NCT06977074	Phase 2	Recruiting	Sun Yat-sen University
JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC	2025/05/13	NCT06969027	Phase 2	Recruiting	Shanghai Junshi Bioscience Co., Ltd.
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors	2025/05/09	NCT06963502	Phase 1	Not yet recruiting	Jiangsu Hansoh Pharmaceutical Co., Ltd.
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction	2025/04/30	NCT06951841	Phase 4	Not yet recruiting	China Medical University, China
BBO-11818 in Adult Subjects With KRAS Mutant Cancer	2025/04/08	NCT06917079	Phase 1	Recruiting	TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer	2025/03/30	NCT06902272	Phase 2	Recruiting	University of Miami
Comparative Study of Adjuvant Therapy for Postoperative Cervical Gastric-type Adenocarcinoma	2025/03/11	NCT06870565	Phase 3	Not yet recruiting	Women's Hospital School Of Medicine Zhejiang University
DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer.	2025/02/11	NCT06820255	Phase 4	Recruiting	Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer	2024/10/18	NCT06648200	Phase 2	Not yet recruiting	Shanghai Pulmonary Hospital, Shanghai, China
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC	2024/10/02	NCT06623656	Phase 2	Recruiting	Weill Medical College of Cornell University

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
Metox	Deseret Biologicals, Inc.	43742-1312	ORAL	12 [hp_X] in 1 mL	5/27/2025
MetDetox	Dr. Donna Restivo DC	62185-0062	ORAL	12 [hp_X] in 1 mL	5/23/2025

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Related News

HER2-Positive Gastric Cancer Pipeline Shows Robust Activity with 20+ Companies Developing Novel Therapies

18 days ago

DelveInsight's 2025 pipeline report reveals over 20 companies actively developing more than 20 innovative therapies for HER2-positive gastric cancer treatment.

FDA Signals Potential Traditional Approval Pathway for Genelux's Olvi-Vec in Platinum-Resistant Ovarian Cancer

4 months ago

FDA indicates that Genelux's ongoing Phase 3 OnPrime/GOG-3076 trial could potentially support traditional approval for Olvi-Vec in platinum-resistant/refractory ovarian cancer without requiring a separate confirmatory study.

Platinum Chemotherapy Shortage Shows No Impact on Short-term Mortality in Advanced Cancer Patients

5 months ago

• A comprehensive cohort study reveals that despite a 15.1% decline in platinum chemotherapy utilization during the 2023 shortage, there was no significant increase in short-term mortality among advanced cancer patients. • Analysis of 11,797 adults with advanced solid cancers showed an adjusted hazard ratio of 1.0 (95% CI, 0.94-1.07) for mortality during the shortage period compared to the previous year. • Researchers emphasize the need for securing robust supply chains for essential anticancer drugs, with further studies required to assess long-term impacts and healthcare system burden.

Exercise Shows Promise in Managing Chemotherapy-Induced Neuropathy for Ovarian Cancer Patients

7 months ago

A comprehensive review reveals that exercise interventions, particularly aerobic activities, may significantly improve chemotherapy-induced peripheral neuropathy symptoms in ovarian cancer patients.

Metabolomics Predicts Platinum Resistance in Gynecologic Cancers

8 months ago

A metabolomics study shows potential in predicting platinum resistance in gynecologic cancers, offering insights into personalized treatment strategies.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access